

### Republic of the Philippines

#### PHILIPPINE HEALTH INSURANCE CORPORATION



Citystate Centre, 709 Shaw Boulevard, Pasig City Call Center (02) 441-7442 Trunkline (02) 441-7444 www.philhealth.gov.ph

#### PHILHEALTH CIRCULAR No. 2014 - 0030

TO ALL PHILHEALTH MEMBERS, ACCREDITED

LEVELS 1, 2 AND 3 GOVERNMENT HOSPITALS,

DOH LICENSED/CERTIFIED DRUG ABUSE TREATMENT

AND REHABILITATION CENTERS

PHILHEALTH REGIONAL OFFICES AND ALL OTHERS

CONCERNED

**SUBJECT** Medical Detoxification Package

#### T. BACKGROUND AND RATIONALE


One of the major thrusts of the Philippine Health Agenda 2016-2022 is to address the triple burden of disease of which substance abuse is included in the top 20% of the most burdensome diseases of the country. The World Health Organization refers to substance abuse as the "harmful or hazardous use of psychoactive substances."

Recent estimates by the Dangerous Drugs Board show that there are 1.8 million drug users in the Philippines, of which the majority or 91% of drug use is methamphetamine. It is a highly addictive stimulant drug that leads to a chronic and relapsing disease caused by chemical and molecular changes in the brain resulting to severe structural and functional damage in areas associated with memory and emotion.

The Philippine Health Insurance Corporation (PhilHealth), in its mandate to provide health insurance coverage for all Filipinos, supports the current government's efforts in the fight against drugs and is one with other agencies' goal in the achievement of long term abstinence from the use of illicit substances.

Pursuant to PhilHealth Board Resolution No. 2159, s. 2016, PhilHealth shall ensure the provision of the minimum standards of medical interventions to safely manage the acute physical symptoms of withdrawal associated with stopping drug use through a medical detoxification package.

However, it is emphasized that medical detoxification is only the first stage or the precursor to effective drug addiction treatment. Medical detoxification must be implemented together with the collaborative and the concerted efforts of pertinent agencies that shall address the challenges of drug addiction in terms of the personal, health and societal aspects of drug rehabilitation.



Benefits Development and Research Department

Page 1 of 6







#### II. **GENERAL RULES**


1. The provision of in-patient services by accredited levels 1, 2, and 3 government hospitals and Drug Abuse Treatment and Rehabilitation Centers licensed/certified by the Department of Health (DOH) to be accredited by PhilHealth for the first stage of drug addiction treatment shall be covered under the medical detoxification package.

If there is documented indication to treat a common co-morbidity associated with withdrawal symptoms arising from amphetamine use, the corresponding medical case rates may also be availed as an addition to the medical detoxification package (Annex "MD.1");

- All eligible members and dependents of the National Health Insurance Program (NHIP) who need to undergo medical detoxification can avail of this package as a one-time benefit availment;
- 3. The No Balance Billing (NBB) Policy shall be applicable to indigent, sponsored, "kasambahay", lifetime and senior citizen categories who are admitted in ward accommodation in accredited government HCIs. In the event that they opt to choose a private accommodation, they shall waive the privilege of the no balance billing, thus, they may be charged by the provider the corresponding co-pay;
- 4. Co-pay of PhilHealth members admitted in government HCIs who are not eligible to NBB should not exceed the package rate for medical detoxification;
- Applicable professional fees in ward accommodation under the no balance billing shall be 25% of the package rate;

Should there be an indication for the management of co-morbidity, the professional fees prescribed in the corresponding medical case rates shall be added to the total professional fees;

- 6. Rules on pooling of professional fees for government facilities shall apply;
- 7. Accredited HCIs providing the services for medical detoxification shall be subject to the rules of the Health Care Provider Assessment System (HCP PAS) and shall be disseminated in a separate issuance.
- 8. Specific policy and guidelines for accrediting DOH licensed/certified Drug Abuse Treatment and Rehabilitation Centers shall be disseminated in a separate issuance.




#### CRITERIA, MINIMUM STANDARDS OF CARE AND PACKAGE RATE III.

- 1. Criteria for availment of the medical detoxification package are the following:
  - a. Eligible PhilHealth member or dependent;
  - b. Positive qualitative and/or quantitative urine test for methamphetamine;
  - c. Current history of methamphetamine (shabu) use including other amphetaminetype stimulants such as cocaine and methylene dioxymethamphetamine (ecstasy) or combination of these, with signs and symptoms of acute toxicity certified by the attending health care provider (Annex "MD.1").
- The minimum standards of care included in the medical detoxification package lists the mandatory services to be provided by the accredited HCI are shown in Table 1:

Table 1. Mandatory and other services for medical detoxification

	Mandatory Services	Other services	
Screening	Physical examination		
	Mental status examination	-	
	Neurological examination		
Diagnostics	Urine qualitative or quantitative test for	-	
	methamphetamine or amphetamine		
	type stimulants		
	Alanine aminotransferase(ALT) (baseline)		
	Aspartate aminotransferase (AST) (baseline)		
	Complete blood count		
	Fasting blood sugar or random blood sugar		
	Urine pH		
	Serum Na, K, Cl		
	Creatinine		
	BUN		
	CPK-MM or (CK total – CK MB)		
	ECG		
	Chest x-ray		
Medicines	D <sub>5</sub> 0.9 NaCl (adult) OR	As indicated only:	
	D <sub>5</sub> 0.3 NaCl (pedia)	Activated charcoal	
		Sodium sulfate	
		Vitamin B complex	
		Benzodiazepine	
		Antipsychotic medicines	
		D50-50	
		Acidification therapy with	
		ascorbic acid	



The package rate for medical detoxification shall be P10,000.00.

Benefits Development and Research Department

Page 3 of 6

#### IV. **CLAIMS FILING**


- The accredited HCI shall file claims according to existing policies of PhilHealth;
- All claims shall be filed by the accredited HCI in behalf of the clients. There shall be no direct filing by PhilHealth members;
- The package code for medical detoxification is MD01;
- A documented co-morbidity associated with withdrawal symptoms during drug treatment may be filed as an additional claim (Annex "MD.2") to the medical detoxification package;

Table 2. Claim application, code, amount and filing schedule

Claim application	Code	Amount (Php)	Filing schedule
Medical detoxification	MD01	10,000	Within 60 calendar
Co-morbidity	ICD-10	Applicable case rate	days after discharge from the accredited HCI

For all intents and purposes, there may or may not be an associated co-morbidity among clients undergoing medical detoxification. Thus, only one (1) major comorbidity can be filed in addition to the medical detoxification package. The accredited HCI shall attach the checklist of co-morbidity form (Annex "MD.2") to the claims application for submission to PhilHealth. The attending accredited physician shall affix his/her signature to signify the truth and correctness of the said co-morbidity;

- To file a claim for reimbursement, the accredited HCI shall submit a claim application and submit the following to PhilHealth:
  - a. PhilHealth Benefit Eligibility Form (PBEF) printout;
  - b. When the PBEF print-out indicates that the patient is not eligible to avail of PhilHealth benefits, the applicable documents may be attached (i.e. certificate of PhilHealth contributions, Claim Form 1, photocopy of official receipt of latest PhilHealth contribution, updated PhilHealth Member Registration Form or PMRF)
  - c. Properly accomplished Claim Form 2
    - i. Part I. Fill out item numbers 1, 2, 3;
    - ii. Part II. Fill out item numbers 1, 2, 3, 4, 5, 6, 7, 8b, 10;
    - iii. For Part II, number 8b, write the package code for medical detoxification
  - iv. If with co-morbidity, fill out Part II, Item 9a.
  - v. For Part II, item number 10, the attending physician must be PhilHealth accredited and must accomplish this part;



Page 4 of 6



- vi. Part IIIA. If without co-pay, check the first box. If with co-pay, check the second box. Completely fill out the required information indicated in the corresponding checked item. The statement of account shall be attached to the claim application;
- vii. Part IIIB. Accomplish this part;
- viii. Part IV. Accomplish this part.
- d. Checklist of Mandatory and Other Services for Medical Detoxification (Annex "MD.3")
- e. Detoxification Treatment Plan (Annex "MD.4")
- f. Photocopy of completely accomplished Satisfaction Questionnaire (Annex "MD.5")
- g. Checklist of Requirements for Reimbursement of Medical Detoxification Package (Annex "MD.6")
- 6. The List of signs and symptoms of acute toxicity (Annex "MD.1") and the results of diagnostic and laboratory tests are NOT required as attachments to the claim. However, these should be attached to the patient's chart and shall be checked during monitoring;
- 7. The Satisfaction Questionnaire (Annex "MD.5") shall be administered to all clients prior to discharge from the accredited HCI. These are validated during monitoring and shall be used as basis of the Corporation for benefits enhancement, policy research and quality improvement purposes;
- Rules on late filing shall apply;
- 9. If the delay in filing of claims is due to natural calamities, or other fortuitous events, the accredited HCI shall be accorded an extension period of 60 calendar days as stipulated in Section 47 of the Implementing Rules and Regulation (IRR) of the National Health Insurance Act of 2013 (Republic Act 7875, as amended by RA 9241 and RA 10606).



Payments shall be given as a single tranche to the accredited HCI.

#### POLICY REVIEW

Pursuant to PhilHealth Circular No. 035-2015, a regular policy review shall be conducted in collaboration with all relevant stakeholders, experts and technical staff representatives from the Corporation.

Benefits Development and Research Department

Page 5 of 6



VI.







#### VII. **EFFECTIVITY**

This circular shall take effect for all admissions 15 calendar days after its publication in the Official Gazette or in a newspaper of national circulation and shall be deposited thereafter at the Office of the National Administrative Register, University of the Philippines Law Center.

#### VIII. ANNEXES

The following annexes may be downloaded from the PhilHealth website: www.philhealth.gov.ph

- 1. List of signs and symptoms of acute toxicity (Annex "MD.1")
- 2. Co-morbidity Checklist (Annex "MD.2")
- 3. Checklist of Mandatory and Other Services for Medical Detoxification (Annex "MD.3")
- 4. Detoxification Treatment Plan (Annex "MD.4")
- 5. Satisfaction Questionnaire (Annex "MD.5")
- 6. Checklist of Requirements for Reimbursement of Medical Detoxification Package (Annex "MD.6")
- 7. Definition of terms (Annex "MD.7")
- 8. Pathway for Medical Detoxification (Annex "MD.8")

MON F. ARISTÓZA, IR. Acting President & CEO

Subject: Medical Detoxification Package

Benefits Development and Research Department

Page 6 of 6


# Signs and Symptoms of Acute Toxicity with Amphetamine Type Stimulant

### I. Symptoms

	Nausea	Headache
	Vomiting	Excessive sweating
	Diarrhea	Tremors
	Behavioral changes	Delirium
	Hyperpyrexia	
	Hypertension	Mental status exam:
0	Signs of circulatory collapse	☐ Hallucinations
	Arrhythmias	☐ Paranoid ideations
□	Dilated pupils	☐ Panic states
	Pallor or flushing	
	Tremors	

### II. Hyperactivity Rating Scale for Amphetamine Overdose

I IT	1 4	Restlessness	Ц	Diaphoresis	
		Irritability		Mydriasis	
		Insomnia		Flushing	
~		Tremor			
		Hyperreflexia			
2+		Hyperactivity		Extrasystoles	
		Confusion		Mild fever	
		Hypertension		Sweating	
		Tachypnea			
3+		Delirium		Tachypnea	
ľ		Mania		Arrhythmias	
į		Self-inju <del>ry</del>		Hyperpyrexia	
		Marked hypertension			
4+		Above symptoms plus:			
		Convulsions			
		Coma			
		Circulatory collapse			
		OR death	-		





Citystate Centre, 709 Shaw Boulevard, Pasig City Call Center (02) 441-7442 Trunkline (02) 441-7444 www.philhealth.gov.ph



#### Annex "MD.2 - Co-morbidity Checklist"

HEALTH CARE INSTITUTION (HCI)
ADDRESS OF HCI
CLIENT (Last name, First name, Middle name, Suffix)
PHILHEALTH ID NUMBER OF CLIENT
MEMBER (if client is a dependent) (Last name, First name, Middle name, Suffix)
PHILHEALTH ID NUMBER OF MEMBER


#### **CO-MORBIDITY CHECKLIST**

Instruction: Place a check mark ( ) to one (1) major co-morbidity

C	CO-MORBIDITY	ICD.10	YES
	I. Substance use disorder		1
	Poisoning by Psychostimulants with abuse potential	T43.6	
	Mental and behavioural disorders due to use of cocaine	F14	
	Mental and behavioural disorders due to use of other stimulants	F15	
	Mental and behavioural disorders due to multiple drug use and use of other psychoactive substances	F19	
	II. Psychosis		
	Psychotic disorders	F23	
	Induced delusional disorder; Folie à deux; Induced paranoid disorder; Induced psychotic disorder	F24	
	Schizoaffective disorders	F25	
	Other nonorganic psychotic disorders; Chronic hallucinatory psychosis	F28	
	Unspecified nonorganic psychosis; Psychosis	F29	1
٦	Hypomania; Mania with or without psychotic symptoms, Manic episode	F30	
_	Bipolar affective disorder	F31	
	Mild to severe depressive episodes	F32	
	Recurrent depressive disorder	F33	
ĺ	Depressive personality disorders; anxiety depression	F34	
	Mania without psychotic symptoms	F35	
	III. Ischemic heart disease with myocardial infarction		
	Acute transmural myocardial infarction	I21	
	Subsequent myocardial infarction	122	

As of October 2016

Page 1 of 2 of Annex MD.2









CO-N	ORBIDITY	ICD.10	Yes
IV. D	ilated cardiomyopathy	I42	
V. H	ypertensive crisis	T10.1	
	Hypertension Stage II	I10.1	
VI. St	roke		
	Hemorrhagic Stroke - Subarachnoid hemorrhage	160	T
	Hemorrhagic Stroke – Intracerebral hemorrhage	I61	1
	Hemorrhagic Stroke – Acute subdural hemorrhage	162	
	Cerebral infarction	I63	
VII.	Seizures  Epileptic seizures related to alcohol; Epileptic seizures related to drugs	G40.5	
VIII.	Acute renal failure  Acute renal failure with tubular necrosis; Tubular necrosis  NOS; Acute Tubular necrosis; Renal Tubular necrosis	N17.0	
IX. G	astrointestinal		1
	Acute vascular disorders of intestine; Acute fulminant ischaemic colitis; Acute intestinal infarction; Acute small intestine ischaemia; Mesentric artery embolism; Mesentric vein embolism; Mesentric artery infarction; Mesentric vein infarction; Mesentric artery thrombosis; Mesenteric vein thrombosis; Subacute ischaemic colitis	K55.0	

Confome by:	Certified true and correct by:
(Printed name and signature) Client/Parent/Guardian	(Printed name and signature) Attending Physician
•	PhilHealth Accreditation No.



As of October 2016





Citystate Centre, 709 Shaw Boulevard, Pasig City Call Center (02) 441-7442 Trunkline (02) 441-7444 www.philhealth.gov.ph

#### Annex "MD.3 - Checklist of Mandatory Services"

HEALTH CARE INSTITUTION (HCI)
ADDRESS OF HCI
PATIENT (Last name, First name, Middle name, Suffix)
PHILHEALTH ID NUMBER OF PATIENT
MEMBER (if patient is a dependent) (Last name, First name, Middle name, Suffix)
PHILHEALTH ID NUMBER OF MEMBER


#### CHECKLIST OF MANDATORY AND OTHER SERVICES **Medical Detoxification Package**


Place a (1) in the status column if DONE or NA if not applicable.

ł	MANDATORY AND OTHER SERVICES	Status
, [	1. Screening	
	a. Physical examination	
	b. Mental status examination	
	c. Neurological examination	
	2. Diagnostics	
	a. Urine qualitative or quantitative test for methamphetamine or amphetamine type stimulants	
	b. Alanine aminotransferase(ALT) (baseline)	
	c. Aspartate aminotransferase (AST) (baseline)	
	d. Complete blood count	
	e. Fasting blood sugar or random blood sugar	
٠.	f. Urine pH	
4	g. Serum Na, K, Cl	
	h. Creatinine	
STER NET Date:	i. BUN	
5 5 G	j. CPK-MM or (CK total – CK MB)	
MASTER DOCUMENT	k. ECG	
N O	l. Chest X-ray	

As of October 2016

Page 1 of 2 of Annex MD.3









### Place a (1) in the status column if DONE or NA if not applicable.

MANDATORY AND OTHER SERVICES	Status
3. Medicines	
a. D <sub>5</sub> 0.9 NaCl (adult) or D <sub>5</sub> 0.3 NaCl (pedia)	
b. Activated charcoal, as indicated	
c. Sodium sulfate, as indicated	
d. Vitamin B complex, as indicated	
e. Benzodiazepine, as indicated	
f. Antipsychotic medicines, as indicated	
g. D50-50, as indicated	
h. Acidification therapy with ascorbic acit, as indicated	

Certified true and correct by:	Certified true and correct by:
(Printed name and signature) Attending Physician	(Printed name and signature) Executive Director/Chief of Hospital/ Medical Director/ Medical Center Chief
PhilHealth Accreditation No.	PhilHealth Accreditation No.
Date signed (mm/dd/yyyy)	Date signed (mm/dd/yyyy)
-	C .f 1

Conforme by:	
(Printed name and signature) Patient/Parent/Guardian	_
Date signed (mm/dd/yyyy)	_



As of October 2016



Citystate Centre Building, 709 Shaw Boulevard, Pasig City Healthline 441-7444 www.philhealth.gov.ph



#### Annex "MD.4 - Detoxification Treatment Plan"

## DETOXIFICATION TREATMENT PLAN Medical Detoxification

ADDRESS OF HCI	
CLIENT (Last name, First name, Midd	le name, Suffix)
PHILHEALTH ID NUMBER OF CL	IENT
MEMBER (if cleient is a dependent) (L	ast name, First name, Middle name, Suffix)
PHILHEALTH ID NUMBER OF ME	EMBER
DETOXIFIC	ATION TREATMENT PLAN
<b>&gt;</b> 1	
≥1 Confome by:	Certified true and correct by:
Confome by:  (Printed name and signature)	(Printed name and signature)
Confome by:  © (Printed name and signature) Client/Parent/Guardian	,



Citystate Centre, 709 Shaw Boulevard, Pasig City Call Center (02) 441-7442 Trunkline (02) 441-7444 www.philhealth.gov.ph



Annex "MD.5 - Satisfaction Questionnaire"


### Satisfaction Questionnaire

Instruction: We would like to know how you feel about the services that pertain to the Medical Detoxification Package in order that we can improve and meet your needs. This survey will only take a few minutes. Please read the items carefully. If you need to clarify items or ask questions, you may approach your friendly health care provider or you may contact PhilHealth call center at 441-7442. Your responses will be kept confidential and anonymous.

	F	of items 1 to 2, please tick on the		
	aŗ	propriate box.	5.	In general, how would you rate the
				health care professionals that provided
	1.	Respondent's age is:		the services for the medical
		☐ 19 years old & below		detoxification package in terms of
		☐ between 20 to 35		doctor-client relationship?
		□ between 36 to 45		□ excellent
		☐ between 46 to 55		☐ satisfactory
		□ between 56 to 65		☐ unsatisfactory
		☐ above 65 years old		☐ don't know
	2.	Sex of respondent	6.	In your opinion, by how much has your
		□ male		HCI expenses been lessened by availing
		☐ female		of the PhilHealth benefit package?
				☐ less than half
		or items 3 to 7, please select the one		☐ by half
		est response by ticking the appropriate		more than half
	bo	OX.		□ don't know
	3.	How would you rate the services	7.	Overall patient satisfaction (PS mark) is:
		received from the health care institution		□ excellent
		(HCI) in terms of availability of		☐ satisfactory
		medicines or supplies needed for the		unsatisfactory
		treatment of your condition?		□ don't know
		☐ adequate	_	
		☐ inadequate	8.	If you have other comments, please
		don't know		share them below:
_	=	How would you got the national or		
-	<u></u>	How would you rate the patient's or family's involvement in the care of the		
ŀ		client?		
, (	 J o	□ excellent		
	JWE Date:	☐ satisfactory		
. ?	₹	unsatisfactory		
Č	5-/	☐ don't know		
1	Desc. 114/1	La don t know		
	- 7	Thank you. Your feedl	hack is i	important to usl
	ပ္ပိ	Thank you. Tout leed	Jack 13	amportant to usi

As of October 2016

Page 1 of 1 of Annex MD.5











Citystate Centre, 709 Shaw Boulevard, Pasig City Call Center (02) 441-7442 Trunkline (02) 441-7444 www.philhealth.gov.ph



#### Annex "MD.6 - Checklist of Requirements for Reimbursement"

	-
, Suffix)	_
	<b></b>
, First name, Middle name, Suf	fix)
	<b>I</b>
ENTS FOR REIMBURSEM ication Package	ENT
	Please Check
ot (Annex MD.6)	
PhilHealth Benefit Eligibility	
· · · · · · · · · · · · · · · · · · ·	
Anney MD 3)	
milaire (Aimex WID.5)	
Certified true and correct by:	
(Printed name and	signature)
Philffealth Accreditation No.	
	First name, Middle name, Suffication Package  at (Annex MD.6) PhilHealth Benefit Eligibility  Annex MD.3)  Certified true and correct by:  (Printed name and Attending PhysphilHealth

As of October 2016

Page 1 of 1 of Annex MD.6

### **Definition of Terms**

Addiction

. . .

The repeated use of a psychoactive substance or substances, to the extent that the user (referred to as an addict) is periodically or chronically intoxicated, shows a compulsion to take the preferred substance (or substances), has great difficulty in voluntarily ceasing or modifying substance use, and exhibits determination to obtain psychoactive substances by almost any means.

Confirmatory test

An analytical test using a device, tool or equipment with a different chemical or physical principle that is more specific which will validate and confirm the result of the screening test.

Dangerous drugs

Include those listed in the Schedules annexed to the 1961 Single Convention on Narcotic Drugs, as amended by the 1972 Protocol, and in the Schedules annexed to the 1971 Single Convention on Psychotropic Substances as enumerated in the attached annex which is an integral part of this Act.

Drug abuse


In the context of international drug control, drug abuse constitutes the use of any substance under international control for purposes other than medical and scientific, including use without prescription, in excessive dose levels, or over an unjustified period of time.

Intoxication

A condition that follows the administration of a sufficient amount of a psychoactive substance and which results in disturbances in the level of consciousness, cognition, perception, judgement, affect, behaviour, or other psychophysiological functions and responses.

Medical detoxification

The initial and acute stage of drug treatment.



The process by which a person who is dependent on a psychoactive substance ceases use, in such a way that minimizes the symptoms of withdrawal and risk of harm. While the term "detoxification" literally implies a removal of toxic effects from an episode of drug use, in fact it has come to be used to refer to the management of rebound symptoms of neuroadaptation, that is, withdrawal and any associated physical and mental health problems.

Methamphetamine hydrochloride commonly known as "Shabu", "Ice", "Meth", or by its any other name. Refers to the drug having such chemical composition, including any of its isomers or derivatives in any form.

Methylenedioxymethamphet amine (MDMA)

commonly known as "Ecstasy", or by its any other name. Refers to the drug having such chemical composition, including any of its isomers or derivatives in any form.

Rehabilitation

In the field of substance use, the process by which an individual with a drug-related problem achieves an optimal state of health, psychological functioning and social well-being.

Screening

A rapid procedure designed to detect individuals who have a substance abuse problem.

Substance abuse

A maladaptive pattern of substance use manifested by recurrent and significant adverse consequences related to the repeated use of substances. There may be repeated failure to fulfil major role obligations, repeated use in situations in which it is physically hazardous, multiple legal problems, and recurrent social and interpersonal problems.

Substance dependence

A cluster of cognitive, behavioural and physiological symptoms indicating that the individual continues use of the sub-stance despite significant substance-related problems. There is a pattern of repeated self-administration that usually results in tolerance, withdrawal and compulsive drug-taking behaviour.

Substance use disorder

Any mental or behavioural disorder resulting from the use of one or more psychoactive substances, whether or not medically prescribed. The substances specified are alcohol, opioids, cannabinoids, sedatives or hypnotics, cocaine, other stimulants (including caffeine), hallucinogens, tobacco, and volatile solvents. The clinical states that may occur include acute intoxication, harmful use, dependence syndrome, withdrawal state, withdrawal state with delirium, psychotic disorder, late-onset psychotic disorder and amnesic syndrome.



Treatment


The process that begins when psychoactive substance abusers come into contact with a health provider or any other community service and may continue through a succession of specific interventions until the highest attainable level of health and well being is reached". More specifically, treatment may be defined "... as a comprehensive approach to the identification, assistance, ... (and) ... health care ... with regard to persons presenting problems caused by the use of any psychoactive substance".

Withdrawal

Refers to either the individual symptoms of, or the overall state (or syndrome), which may result when a per- son ceases use of a particular psychoactive drug upon which they have become dependent or after a period of repeated exposure.

Withdrawal syndrome

A group of symptoms of variable severity which occur on cessation or reduction of drug use after a prolonged period of use and/or in high doses. The syndrome may be accompanied by signs of both psychological and physiological disturbance.



## CLINICAL PATHWAY MEDICAL DETOXIFICATION

#### **INCLUSION CRITERIA:**

- 1. Positive qualitative and/or quantitative urine test for methamphetamine;
- 2. Current history of methamphetamine (shabu) use including other amphetamine- type stimulants such as cocaine and methylene dioxymethamphetamine (ecstasy) or combination of these, with signs and symptoms of acute toxicity certified by the attending health care provider.

NAME:	<u> </u>	AGE: GENDER:	
ADDRESS:	<u> </u>	CIVIL STATUS:	
CONTACT NUM	//BER:	HOSPITAL NUMBER:	
EDUCATIONAL	ATTAINMENT:	OCCUPATION:	
	<u></u>	DAY 1	
.HISTORY & P.		PHYSICIAN'S NOTES:	VARIANCE
A. Exposu			-
	Number of Agents:	○ Single ○ Multiple	
	Substance:	<ul><li>○ Methamphetamine</li><li>○ MDMA</li><li>○ Other Stimulants</li></ul>	
	Route of	Olngestion Olnjection:	
	Exposure:	Inhalation Mixed:	
	Type of Exposure:		
	Time since last Exposure:	Years Months Weeks Days	
4 1/0	Location of Exposure:	<ul><li>○ Home</li><li>○ Neighbor/Friend's place</li><li>○ Workplace</li><li>○ Others</li></ul>	

As of October 2016

NAME:		AGE: GENDER:	
ADDRESS: _		CIVIL STATUS:	<del></del>
CONTACT N	UMBER:	HOSPITAL NUMBER:	
EDUCATION	IAL ATTAINMEN	T:OCCUPATION:	<del></del>
		nava.	
B. Signs a	and Symptoms	DAY 1	VARIANCE
	o Substance		- Tritizates
Use?	o substance		
Yes	No		
		1. Nausea	]
ĺŏ		2. Vomiting	
		3. Diarrhea	
000000000000000000000000000000000000000	000000000000000000000000000000000000000	4. Behavioral Changes	
		5. Hyperpyrexia	
		6. Hypertension	
		7. Signs of circulatory collapse	
		8. Arrhythmias	
l Ö		9. Dilated pupils	
l O	O	10. Pallor or flushing	
		11. Tremors	
		12. Headache	
		13. Excessive sweating	1
		14. Delirium	
	Ò	15. Palpitations	
lõ	Ŏ	16. Mental Status Exam	
lŏ	lŏ	17. Hallucinations	
		18. Paranoid ideations	
		19. Panic states	
		SCALE FOR AMPHETAMINE OVERDOSE	
	1+		
	14	Restlessness Diaphoresis Irritability Mydriasis	
]		Insomnia Flushing	
		Tremor Hyperreflexia	
	2+	O Hyperactivity O Extrasystoles	-
		Confusion Mild Fever	
		Hypertension Sweating	
		<b>○</b> Tachypnea	
	3+	○ Delirium ○ Tachypnea	
)))		Mania Arrhythmias	
7		Self-injury Hyperpyrexia	
	<del></del>	Marked hypertension	
Date	4+	Above symptoms plus:	
5°.		Convulsions Coma	
A DOCUMENTA WA		Circulatory Collapse Death	
۵ <sub>7</sub> /			
£			
g			
As of Octob	or 2016	т	Page 2 of 10
	CI 2010	ľ	age 2 OL IV

		AGE:		
		CIVIL STATI		
		T:OCCUPATIO	SPITAL NUMBER:	
LDOCATIONA	LAI IAIMINILIA		DI4	<u> </u>
		DAY 1		·
III. DIAGNOST	<del>,</del>		<del></del>	VARIANCE
YES	NO O	a. Urine qualitative or quantitative test for Map or amphetamine type stimulants	O Positive Negative	
0	0	a. Urine Ph	○5.0 ○6.0 ○6.5 ○7.0 ○7.5 ○8.0 ○9.0	
. O	0	b. Alanine aminotransferase (ALT) (baseline)	ļ	
0	0	c. Aspartate aminotransferase (AST) (Baseline)		
Ο	0	d. Complete blood count	Hgb: Hct: WBC: Plt. Ct Differential Count:	
0	0	e. FBS or RBS		
0	0	f. Electrolytes	Na: K: Cl:	
0	0	g. Creatinine		
0	0	h. BUN		
0	0	i. CPK-MM or CK total – CK MB)		
	0	j. ECG		
	0	k. Chest X-ray		

As of October 2016

Page 3 of 10

		AGE			
		CIVI			
				L NUMBER:	
EDUCATIONA	L ATTAINMEI	NT:OCC	UPATION:		<u></u>
•		DAY 1	Ĭ.		
IV. THER	APEUTICS				VARIANCE
YES	NO		# of	Doses (If Yes)	
0	0	a. D5 0.9 NaCl or D5 0.3 NaCl			
000000	0	b. Activated Charcoal	<u> </u>		
0	0	c. Sodium Sulfate			_
Q	) O	d. d. Ascorbic Acid			-
Q	Q	e. Diazepam			-
0		Others			-
V. SUPPO	ORTIVE	<u> </u>			<del>                                     </del>
YES	NO				
0	0	Refer to Psychiatry service			
Ŏ	Ŏ	Refer to other specialty service	:		
		(as needed)	_		
ACTIVATED B	Y:	A	CKNOWLEDG	SED BY:	
844	ling Observations	(Name and Cianatura)	B/	o on Duka (Norse ess	d Ciamatura)
		(Name and Signature)		e on Duty (Name and	
rillinealth Ac	creditation N	o P	AC LICENSE IV	o	<del></del>

VAR	IANCE CODES				
	A. CLIENT		B. CAREGIVER		C. SYSTEM
1.	Client too sick	1.	Physician provider error	1.	Bed availability
2.	Comorbid interference	2.	Lack of or inadequate	2.	Schedule conflict
3.	Client cognitive status		documentation	3.	Consultant unavailable
4.	Client/family decision	3.	Time orders were written	4.	Therapist unavailable
5.	Psychological/emotional status	4.	Time orders were written	5.	Results/data unavailable
6.	Inability to learn skill needed	5.	Orders outside clinical pathway	6.	Supply/equipment unavailable
7.	Inadequate family/social		parameters	7.	Department closed
	support	6.	Physician response time	8.	Placement unavailable
8.	Not indicated at this time	7.	Other provider response time	9.	Home health care unavailable
9.	Unable to return to		,	10.	. Pending payer approval
	preadmission environment			11.	. Lack of equipment
10.	. Client condition warrants early			12.	. Not applicable (explain)
	-discontinuance			13	. Other (explain)
11	, Client noncompliance				
	Caregiver difficulties				

MASTER

Ascof October 2016

GENDER:

## CLINICAL PATHWAY MEDICAL DETOXIFICATION


#### **INCLUSION CRITERIA:**

NAME:

- 1. Positive qualitative and/or quantitative urine test for methamphetamine;
- Current history of methamphetamine (shabu) use including other amphetamine- type stimulants such as cocaine and
  methylene dioxymethamphetamine (ecstasy) or combination of these, with signs and symptoms of acute toxicity
  certified by the attending health care provider.

AGE: \_\_\_\_

ADDRESS:		CIVIL STATUS: HOSPITAL NUMBER:	
		DAY 2	
<ol> <li>Signs and</li> </ol>	Symptoms		VARIANCE
Secondary to Subs	tance Use?		<u> </u>
Yes 000000000000000000000000000000000000	200000000000000000000000000000000000000	<ol> <li>Nausea</li> <li>Vomiting</li> <li>Diarrhea</li> <li>Behavioral Changes</li> <li>Hyperpyrexia</li> <li>Hypertension</li> <li>Signs of circulatory collapse</li> <li>Arrhythmias</li> <li>Dilated pupils</li> <li>Pallor or flushing</li> <li>Tremors</li> <li>Headache</li> <li>Excessive sweating</li> <li>Delirium</li> <li>Palpitations</li> <li>Mental Status Exam</li> <li>Hallucinations</li> <li>Paranoid ideations</li> <li>Panic states</li> </ol>	



<u> </u>		AGE: GEN	
		CIVIL STATUS: HOSPITAL NUMBER:	
		OCCUPATION:	
EDOCATIONAL			
		DAY 2	
II. HYPERACTIVI	TY RATING SCALE	FOR AMPHETAMINE OVERDOSE	VARIANCE
1	+	O Restlessness O Diaphoresis	
		Orritability Mydriasis	
		○ Insomnia	
1	••	Confusion Mild Fever	
		O Hypertension Sweating	
		Tachypnea	
3	+	O Delirium Tachypnea	
		○ Mania	
		Self-injury O Hyperpyrexia	
		Marked hypertension	
4	+	Above symptoms plus:	
		○ Convulsions ○ coma	
		OCirculatory Collapse O Death	
III. DIAGNO	OSTICS	(only as needed)	
YES	NO		<del></del> -
		a Florina No.	
0	0	a. Electrolytes Na: K:	
		Cl:	
		<del> </del>	
0	0	b. Creatinine	
		- 9118	
		· c. BUN	-
. 0	0	d. Others	

MASTER	DC: Date: 1/4 1/4	
--------	-------------------	--

NAME: ADDRESS: CONTACT NUMBER: EDUCATIONAL ATTAINMENT:		CIVIL STATUS:HOSPITAL NUMBER:			
		DA	Y 2		
III. THERA	APEUTICS				
YES	NO			# of Doses (If Yes)	VARIANCE
000000	000000	a. D5 0.9 NaCl or b. Activated Char c. Sodium Sulfate d. Ascorbic Acid e. Diazepam f. Others	coal		
ACTIVATED BY:			ACKNOWLEDG		
Attending Physician (Name and Signature) PhilHealth Accreditation No			e on Duty (Name and S nse No.		

A. CLIENT	B. CAREGIVER	C. SYSTEM
1. Client too sick	Physician provider error	1. Bed availability
2. Comorbid interference	2. Lack of or inadequate	2. Schedule conflict
3. Client cognitive status	documentation	3. Consultant unavailable
4. Client/family decision	3. Time orders were written	4. Therapist unavailable
5. Psychological/emotional status	4. Time orders were written	5. Results/data unavailable
<ul><li>6. Inability to learn skill needed</li><li>7. Inadequate family/social</li></ul>	<ol><li>Orders outside clinical pathway parameters</li></ol>	<ol><li>Supply/equipment unavailable</li></ol>
support	6. Physician response time	7. Department closed
8. Not indicated at this time	7. Other provider response time	8. Placement unavailable
Unable to return to preadmission environment		9. Home health care unavailable
10. Client condition warrants early discontinuance		10. Pending payer approval 11. Lack of equipment
11. Client noncompliance		12. Not applicable (explain)
12. Caregiver difficulties		13. Other (explain)



## CLINICAL PATHWAY MEDICAL DETOXIFICATION

#### **INCLUSION CRITERIA:**

- 3. Positive qualitative and/or quantitative urine test for methamphetamine;
- 4. Current history of methamphetamine (shabu) use including other amphetamine- type stimulants such as cocaine and methylene dioxymethamphetamine (ecstasy) or combination of these, with signs and symptoms of acute toxicity certified by the attending health care provider.

NAME:		ER:	
ADDRESS:	CIVIL STATUS:		
CONTACT NUMBER:	HOSPITAL NUMBER:		
EDUCATIONAL ATTAINMENT:	OCCUPATION:		
	DAY 3		
I. Signs and Symptoms		VARIANCE	
Secondary to Substance Use?			
Yes No		1	
	<ol> <li>Nausea</li> <li>Vomiting</li> <li>Diarrhea</li> <li>Behavioral Changes</li> <li>Hyperpyrexia</li> <li>Hypertension</li> <li>Signs of circulatory collapse</li> <li>Arrhythmias</li> <li>Dilated pupils</li> <li>Pallor or flushing</li> <li>Tremors</li> <li>Headache</li> <li>Excessive sweating</li> <li>Delirium</li> <li>Palpitations</li> <li>Mental Status Exam</li> <li>Hallucinations</li> <li>Paranoid ideations</li> <li>Panic states</li> </ol>		



			_	AGE:	GENDER: _	
ADDRESS:		<u> </u>		CIVIL STATUS:		
CONTACT NUM	BER:	<del> </del>	HOS	PITAL NUMBER: _		<u></u>
EDUCATIONAL.	ATTAINMENT:			OCCUPATION:		
W 1000000		DAY		<u> </u>		
	-	FOR AMPHETAMINE OVI		-		VARIANCE
]	l+	)	iaphoresi:	5		
		)	lydriasis ushing			
		)	usiiiig lyperrefle	xia		
	<u></u>	<u> </u>	xtrasystol			
_	-		ild Fever			
		_	weating			
		<b>○</b> Tachypnea	J			
3	J+	O Delirium O Ta	schypnea			
		~	rrhythmia		}	
			yperpyrex	cia .		
		Marked hypertension				
4	<b> +</b>	Above symptoms plus:		_		
		Convulsions	~	coma		
III DIACNI	OCTION .	OCirculatory Collapse		) Death		
III. DIAGNO						
YES	NO					
0	0	a. Urine qualitative	or	( ) Positive		<del></del>
		quantitative test		<b>○</b> Negative		
		Map or ampheta	mine			
	<u></u>	type stimulants				
0	0			<b>○5.0 ○6.0</b>		
		b. Urine Ph		○6.5 ○7.0	1	
				○7.5 ○8.0		
				○9.0		
		a Flastralidas		No.		
		c. Electrolytes		Na:		
			,	K: Cl:		
0	0	d. Creatinine			_	
			,		-	
0	0	e. BUN	;		.	
a _	_	_	_			
		f. CPK-MM or CK to	otal – CK		. ]	
4		MB)	ł		}	
		a Others	ı			
	0	g. Others	<del></del>	<del></del>	<del></del>	
CUIMENT 4/16	L					<del></del>
ರ 11						

As of October 2016

Page 9 of 10

NAME: ADDRESS: CONTACT NUMBER: EDUCATIONAL ATTAINMENT:			CIVIL STATUS: HOSPITAL NUMBER:		
_		DAY 3			
III. THERA	APEUTICS				VARIANCE
YES	NO	<del> </del>		# of Doses (If Yes)	
000000	000000	<ul> <li>a. D5 0.9 NaCl or D5 0</li> <li>b. Activated Charcoal</li> <li>c. Sodium Sulfate</li> <li>d. d. Ascorbic Acid</li> <li>e. Diazepam</li> <li>f. Others</li> </ul>			
	ng Physician (Namo			D BY: on Duty (Name and Sig o No.	•

A. CLIENT	B. CAREGIVER	C. SYSTEM	
<ol> <li>Client too sick</li> <li>Comorbid interference</li> <li>Client cognitive status</li> <li>Client/family decision</li> <li>Psychological/emotional status</li> <li>Inability to learn skill needed</li> <li>Inadequate family/social support</li> <li>Not indicated at this time</li> <li>Unable to return to preadmission environment</li> <li>Client condition warrants early discontinuance</li> <li>Client noncompliance</li> <li>Caregiver difficulties</li> </ol>	<ol> <li>Physician provider error</li> <li>Lack of or inadequate documentation</li> <li>Time orders were written</li> <li>Time orders were written</li> <li>Orders outside clinical pathway parameters</li> <li>Physician response time</li> <li>Other provider response time</li> </ol>	<ol> <li>Bed availability</li> <li>Schedule conflict</li> <li>Consultant unavailable</li> <li>Therapist unavailable</li> <li>Results/data unavailable</li> <li>Supply/equipment unavailable</li> <li>Department closed</li> <li>Placement unavailable</li> <li>Home health care unavailable</li> <li>Pending payer approval</li> <li>Lack of equipment</li> <li>Not applicable (explain)</li> <li>Other (explain)</li> </ol>	

As of October 2016